Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:FEED

Nanovibronix Q1 2026 Earnings Report

Nanovibronix logo
$0.80 -0.03 (-3.52%)
Closing price 04:00 PM Eastern
Extended Trading
$0.79 -0.01 (-0.88%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nanovibronix EPS Results

Actual EPS
-$6.88
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nanovibronix Revenue Results

Actual Revenue
$0.65 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nanovibronix Announcement Details

Quarter
Q1 2026
Date
5/18/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nanovibronix Earnings Headlines

ENvue Medical Launches AI Training Platform Establishing Artificial Intelligence Foundation for Robotic Feeding Tube Navigation
June 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/09/3308809/0/en/envue-medical-launches-ai-training-platform-establishing-artificial-intelligence-foundation-for-robotic-feeding-tube-navigation.html
ENvue Medical Expands into Burn Intensive Care Unit at Major Academic Health Network
June 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/05/3307384/0/en/envue-medical-expands-into-burn-intensive-care-unit-at-major-academic-health-network.html
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
June 15 at 1:00 AM  |  Altimetry (Ad)
ENvue Medical Announces Publication of Landmark Independent Study Highlighting Significant Safety, Time-, and Cost-Saving Benefits of ENvue Navigation Platform in Multi-Hospital System
June 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/03/3306023/0/en/envue-medical-announces-publication-of-landmark-independent-study-highlighting-significant-safety-time-and-cost-saving-benefits-of-envue-navigation-platform-in-multi-hospital-syste.html
ENvue Medical to Showcase ENvue™ Navigation Platform at AACN NTI 2026
May 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297586/0/en/envue-medical-to-showcase-envue-navigation-platform-at-aacn-nti-2026.html
ENvue Medical Secures Three-Year Contract Renewal at 12-Hospital U.S. Health Network as the ENvue™ Navigation Platform Becomes Standard of Care
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3292861/0/en/envue-medical-secures-three-year-contract-renewal-at-12-hospital-u-s-health-network-as-the-envue-navigation-platform-becomes-standard-of-care.html
See More Nanovibronix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanovibronix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanovibronix and other key companies, straight to your email.

About Nanovibronix

Nanovibronix (NASDAQ:FEED) (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company's product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies. Its offerings are intended to be user‑friendly, portable and suitable for repeated application, which supports adoption in ambulatory care and self‑care environments. Nanovibronix emphasizes clinical research and device development to validate therapeutic effects and to support regulatory and reimbursement discussions in the markets it serves.

As a publicly traded entity on the NASDAQ exchange under the ticker FEED, Nanovibronix engages in the full product lifecycle from research and development through manufacturing, regulatory engagement and distribution. The company has historically sought to expand market access through clinical collaborations, distribution partnerships and targeted commercialization initiatives. Detailed, current information about specific products, regulatory clearances, market geographies or executive leadership was not available in the material used to prepare this summary.

View Nanovibronix Profile
Earnings Tools